This archive covers progress in drug policy reform, psychedelic-assisted therapy, harm reduction, and the science behind entheogenic substances. From clinical trials to legal milestones, these stories track how researchers, policymakers, and communities are rethinking humanity’s relationship with mind-altering compounds.
The City Council voted unanimously to decriminalize the non-commercial possession and cultivation of many psychedelics for “religious, spiritual, healing, or personal growth practices.”
The dismissals aim to reverse the racial injustices of drug laws as many of the cases are those of people of color disproportionately incarcerated for drug offenses.
Governor Phil Murphy signed legislation into law in 2019 facilitating a process for the review and vacation of the criminal records of those previously convicted of low-level marijuana offenses.
Over 10,000 offenders and inmates are being released from prisons following the legalization of the plant “Kratom” in Thailand. Legally, these prisoners will be considered as having never committed an offense.
During the study, research, medical, and therapist staff at Numinus will collect data on the safety and effectiveness of MDMA-assisted therapy to inform Health Canada and support making MDMA-assisted therapy available to individuals living with PTSD in Canada.
The decisive 8-3 ruling comes after advocates pushed for decriminalization as a means to reduce drug-fueled cartel violence in the country.
The state-backed Human Rights Commission said 27 executions were recorded in 2020. That is down from 184 the year before, according to rights watchdog Amnesty International.
Psilocybin performed about as well as the SSRI escitalopram as a treatment for moderate-to-severe major depressive disorder, according to a new double-blinded, randomized experiment.
Late last month, the governor signed another bill that expands expungement eligibility for certain convictions, including misdemeanor marijuana possession.
The extremely promising data are the first Phase 3 results to be revealed for any psychedelic-based therapy, paving the way for a landmark US Food and Drug Administration (FDA) approval in 2023.
